UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 03/2012, Volume 55, Issue 3, pp. 742 - 748
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Antiviral agents | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antibiotics. Antiinfectious agents. Antiparasitic agents | Recombinant Proteins - therapeutic use | Isoquinolines - adverse effects | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Diarrhea - epidemiology | Male | Diarrhea - chemically induced | Polyethylene Glycols - therapeutic use | Incidence | Hepatitis C - ethnology | Treatment Failure | Protease Inhibitors - adverse effects | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Headache - chemically induced | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Japan | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Headache - epidemiology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Aged | Viral Nonstructural Proteins - antagonists & inhibitors | Proteins | Hepatitis | Genotype & phenotype | Interferon | Infections | Index Medicus
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Middle Aged | Male | Thiazoles - therapeutic use | Thiazoles - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - adverse effects | Quinolones - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Protease Inhibitors - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Organophosphonates - adverse effects | Drug Therapy, Combination - methods | HIV | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Adults | Protease inhibitors | Proteases | Antiretroviral drugs | Patient satisfaction | Drug therapy | Laboratories | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
BMC infectious diseases, ISSN 1471-2334, 04/2020, Volume 20, Issue 1, pp. 264 - 264
Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Anilides - therapeutic use | Prospective Studies | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Middle Aged | Male | Ritonavir - adverse effects | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical research | Antiviral agents | Liver diseases | Liver | Biological products industry | Biological response modifiers | Infection | Protease inhibitors | Proteases | Medicine, Experimental | Product development | Drug therapy | Hepatitis C virus | Health aspects | Ritonavir | Health services | Chronic infection | Viruses | Hepatocellular carcinoma | Infections | Ribavirin | Genotype & phenotype | Hepatitis | Protease | Drug dosages | Failure | Genotypes | Medical treatment | Proteinase inhibitors | Patients | Ankle | Side effects | Hypotheses | Fibrosis | Interferon | Hepatitis C | Index Medicus | Direct acting anti-viral agents | HCV | AbbVie 3D | Protease inhibitors failure
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2011, Volume 141, Issue 6, pp. 2047 - 2055
Gastroenterology and Hepatology | Drug | Peginterferon-Free | Direct-Acting Antivirals | Clinical Trial | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Acrylates - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Thiazoles - therapeutic use | Oligopeptides - adverse effects | Thiazoles - adverse effects | Viral Load | Acrylates - adverse effects | Oligopeptides - therapeutic use | Protease Inhibitors - adverse effects | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | RNA-Dependent RNA Polymerase - antagonists & inhibitors | Ribavirin - adverse effects | Antiviral Agents - adverse effects | RNA, Viral - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Complications and side effects | Antiviral agents | Care and treatment | Protease inhibitors | Proteases | Universities and colleges | Hepatitis C | Hepatitis C virus | Ribavirin | Anti-HIV agents | Index Medicus | Abridged Index Medicus
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2012, Volume 156, Issue 4, pp. 279 - 290
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Markov Chains | Ribavirin - economics | Humans | Male | Liver Cirrhosis - economics | Liver Neoplasms - etiology | Interleukins - genetics | Protease Inhibitors - adverse effects | Female | Carcinoma, Hepatocellular - etiology | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Quality-Adjusted Life Years | Liver Cirrhosis - drug therapy | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Risk Factors | Decision Support Techniques | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Genotype | Treatment Outcome | Protease Inhibitors - economics | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - economics | Disease Progression | Medication Adherence | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Cost-Benefit Analysis | Interferon-alpha - adverse effects | Antiviral Agents - economics | Hepatitis C, Chronic - genetics | Research | Protease inhibitors | Hepatitis C | Drug therapy | Health aspects | Clinical trials | Genotype & phenotype | Hepatitis | Medical treatment | Index Medicus | Abridged Index Medicus
Journal Article
Current cancer drug targets, ISSN 1568-0096, 2014, Volume 14, Issue 6, pp. 517 - 536
Bortezomib | Proteasome inhibitor | Multiple myeloma | Carfilzomib | Combination therapy | Immunoproteasomes | Resistance to proteasome inhibitors | Ubiquitin-proteasome pathway | Life Sciences & Biomedicine | Oncology | Science & Technology | Ubiquitin-Specific Proteases - antagonists & inhibitors | Humans | Ubiquitin-Protein Ligases - metabolism | Boronic Acids - adverse effects | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Molecular Targeted Therapy | Proteasome Inhibitors - adverse effects | Proteasome Inhibitors - therapeutic use | Proteolysis - drug effects | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Animals | Ubiquitin-Protein Ligase Complexes - metabolism | Ubiquitination - drug effects | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Drug Design | Pyrazines - adverse effects | Proteasome Endopeptidase Complex - metabolism | Multiple Myeloma - enzymology | Ubiquitin-Specific Proteases - metabolism
Journal Article